Clinical Trials Logo

Sarcoidosis clinical trials

View clinical trials related to Sarcoidosis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06396910 Completed - Tuberculosis Clinical Trials

TB and Sarcoidosis Granuloma

Start date: September 1, 2021
Phase:
Study type: Observational

Tuberculosis (TB) and sarcoidosis are both granulomatous diseases. Here we compared the immunological micro-environments of granulomas from TB and sarcoidosis patients using in situ sequencing (ISS) transcriptomic analysis and multiplexed immunolabelling of tissue sections.

NCT ID: NCT06043882 Completed - COVID-19 Clinical Trials

Number of Participants Diagnosed With Sarcoidosis by Bronchoscopic Transbronchial Needle Aspiration After COVID- 2019 .

Start date: November 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about sarcoidosis development after COVID-19 infection. The main question it aims to answer is: - prevalence of Sarcoidosis among patients previously infected with COVID-19. Participants will: - provide previous positive RT-PCR for COVID-19 - Have computed tomography of the Chest with suggestive findings of sarcoidosis - Have bronchoscopic guided biopsies and pathological analysis to detect number of patients with sarcoidosis.

NCT ID: NCT05811962 Completed - Clinical trials for Sarcoidosis, Pulmonary

The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis

SARCO
Start date: January 1, 2014
Phase:
Study type: Observational

The goal of this observational study is to elucidate the role of serum amyloid A (SAA) in the diagnosis and follow-up of sarcoidosis, including its prognostic value. The main questions it aims to answer are: - Whether, at the time of diagnosis, SAA is in correlation with other serum markers of granulomatous inflammation, interstitial disease and pulmonary fibrosis, lung function and radiologic characteristics of intrathoracic sarcoidosis, - Whether increased serum concentrations of SAA at the time of diagnosis act as a prognostic marker of progressive granulomatous inflammation and pulmonary interstitial disease. Patients will undergo standard diagnostic procedures for intrathoracic sarcoidosis, according to WASOG (World association of sarcoidosis and other granulomatous disorders) criteria. Two additional vials of blood will be taken at diagnosis and one vial at follow-up for serum processing and biomarker analysis. Healthy blood donors will represent our group of healthy controls.

NCT ID: NCT05759221 Completed - Clinical trials for Sarcoidosis, Pulmonary

Peripheral Airway Biopsy in Sarcoidosis

Sopranos
Start date: October 20, 2022
Phase: N/A
Study type: Interventional

Airway involvement in sarcoidosis was demonstrated in a meaningful, albeit variable, proportion of patients through biopsy of the central, endoscopically visible airways. Ideally, biopsy of peripheral airways, nowadays possible with the introduction in the market of ultrathin bronchoscopes, might be associated with an increased diagnostic yield for the detection of granulomas.

NCT ID: NCT05311150 Completed - Clinical trials for Sarcoidosis, Pulmonary

An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis

NABS
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

In the diagnosis of patients with sarcoidosis, there is paucity of literature on the diagnostic yield of the endobronchial biopsies obtained with narrow band imaging (NBI) bronchoscopy. The present study aims to compare the diagnostic yield of endobronchial biopsyperformed under direct narrow band imaging or white light bronchoscopy guidance in suspected sarcoidosis.We hypothesize that the use of NBI will improve the yield of endobronchial biopsy in patients with sarcoidosis.

NCT ID: NCT05230693 Completed - Fatigue Clinical Trials

SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue

SPARC
Start date: February 23, 2022
Phase: N/A
Study type: Interventional

Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue. The proposed project will evaluate the usability/feasibility of a smartphone-based stress management application for the self-management of sarcoidosis-associated stress and fatigue.

NCT ID: NCT05181930 Completed - Sarcoidosis Clinical Trials

Nuclear Magnetic Resonance Spectroscopic Analysis of Urinary Metabolome in Sarcoidosis (RMN-SARCURINES)

RMN-SARCURINES
Start date: January 30, 2018
Phase:
Study type: Observational

"Sarcoidosis is a systemic granulomatous disease of unknown cause(s).Determining disease activity is a major element in the treatment decision. 1H- Nuclear magnetic resonance (NMR) spectroscopy allows the identification of biomarkers in different pathologies and in particular in a pilot study of saliva of patients with sarcoidosis. Applications to sarcoidosis are still rare, having concerned only serum and saliva. In this context we hypothesize the existence of a difference in the metabolic products found in the urine of sarcoidosis patients with different degrees of activity and/or disease severity. We designed an analysis of urinary metabolomics in sarcoidosis patient using NMR spectroscopy with multivariate statistical analysis, followed by metabolite identification and pathway analysis. "

NCT ID: NCT05089565 Completed - Sarcoidosis Clinical Trials

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

Start date: December 1, 2021
Phase:
Study type: Observational [Patient Registry]

People with sarcoidosis, particularly those with significant lung and/or cardiac involvement, who become infected with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) are likely at increased risk of complications or death from COVID-19. While SARS-CoV-2 vaccines are highly efficacious in preventing COVID-19 in the general population, whether vaccination provides similar protection in people with sarcoidosis is unknown. The investigators hypothesize that people with sarcoidosis develop less robust antibody and cell-mediated immune responses to SARS-CoV-2 vaccination than healthy individuals, both as a consequence of the disease itself and due to treatment with immunosuppressive medications. This hypothesis will be examined by determining levels of anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) antibody (Specific Aim 1) and measuring SARS-CoV-2-specific activation of peripheral blood T cells (Specific Aim 2) following SARS-CoV-2 vaccination in individuals with sarcoidosis treated and not treated with immunosuppressive medications, in comparison to age- and sex-matched healthy controls. For Specific Aim 1, a second-generation anti-SARS-CoV-2 spike IgG assay calibrated against an independent virus neutralization assay will be utilized. The results of this investigation will address a critical gap in the understanding of vaccine responses in people with sarcoidosis. In addition, the study will contribute knowledge needed to inform clinicians' recommendations to sarcoidosis patients regarding risk of infection after SARS-CoV-2 vaccination, and will help lay the basis for future trials to evaluate the possible benefit of vaccine boosters in individuals with poor immune responses to initial vaccination.

NCT ID: NCT04904939 Completed - Clinical trials for Endobronchial Mucosal Pathology in Pulmonary Sarcoidosis

Endobronchial Mucosal Biopsy in Patients With Suspected Pulmonary Sarcoidosis

Start date: May 15, 2020
Phase: N/A
Study type: Interventional

This prospective interventional study was done between May and September 2020. We included 20 patients from the chest department, Alexandria Main University Hospital (AMUH) with the inclusion criteria of having suspected pulmonary sarcoidosis (based on clinical and radiological presentation) and being ≥18 years of age. The bronchoscopy procedure was done under local anesthesia. Endobronchial biopsies and bronchoalveolar lavage were obtained.

NCT ID: NCT04803617 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease

Start date: January 23, 2017
Phase:
Study type: Observational

Interstitial lung disease (ILD) is a restrictive lung disease characterized by impaired lung function, exercise limitation and skeletal muscle dysfunction. There is limited data on skeletal muscle function in ILD, most of which are focused on the lower limb muscles. The aim of this study were to evaluated the change of pectoralis muscle strength and relationship of pulmonary function with pectoralis muscle strength.